IRIS Archives

Information and Referral and Internet Sightings

IRIS@LISTSERV.ICORS.ORG
Options: Use Forum View

Use Monospaced Font
Show Text Part by Default
Show All Mail Headers

Message: [<< First] [< Prev] [Next >] [Last >>]
Topic: [<< First] [< Prev] [Next >] [Last >>]
Author: [<< First] [< Prev] [Next >] [Last >>]

Print Reply
Subject:
news byte: Strattera
From:
Sylvia Caras <[log in to unmask]>
Reply To:
[log in to unmask]
Date:
Mon, 12 May 2008 11:30:18 -0700
Content-Type:
text/plain
Parts/Attachments:
text/plain (9 lines) 
Eli Lilly and Company announced today that the United States Food and 
Drug Administration has approved Strattera for maintenance treatment of 
Attention-Deficit/Hyperactivity Disorder in children and adolescents. 
Strattera, a selective norepinephrine reuptake inhibitor, is the first 
FDA-approved non-stimulant to treat ADHD in children, adolescents and 
adults.

www.peoplewho.org

ATOM RSS1 RSS2